Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

Completed

Conditions studied: Elevated PSA, Prostate Cancer

In brief

This is a pilot study to determine cancer detection rate of conventional/systematic versus targeted biopsy methods in diagnosis of potentially lethal prostate cancer. This is a diagnostic trial using each patient as his own control.

Key facts

Study ID

NCT02425228

Run by

Jonsson Comprehensive Cancer Center

People needed

300

Starts

2014-12-04

Expected to finish

2018-12-18

Last updated by the study team

2020-07-24

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men undergoing a first-time prostate biopsy driven by PSA elevation to rule out cancer.
• PSA 2.5 - 20 ng/mL
• Prostate volume 20 - 100 cc
• No prior ablation or TURP
• Able to tolerate MRI
• T1c suspect
• Signed informed consent

You may not qualify if…

• Any prior prostate biopsy
• Active bleeding disorder or concurrent use of coumadin or any other anticoagulant, unless anticoagulation can be temporarily stopped for at least 7 days before and 7 days after the biopsy
• Any prostate ablative procedure, including transurethral resection, photovaporization, or electrovaporization
• Any contraindication to MRI (contrast allergy, severe claustrophobia, MRI-incompatible prosthesis) ,
• Palpable prostate mass lesion (i.e., Stage >T1c suspected)
• Any condition that would preclude the subject from getting the required biopsy as stated in the protocol

Where it is running

• UCLA — Los Angeles, California, United States
• University of California Los Angeles — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.